Modified HIV Envelope Immunogens for Broadly Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccine development struggles to elicit broadly neutralizing antibodies (bNAbs) against the envelope glycoprotein (Env), necessitating the development of HIV antigens that can induce such antibodies for the treatment or prevention of HIV-related diseases.
Innovation Solution
Development of modified HIV envelope immunogens with SHIV-evolution identified mutations, including D167N, D167G, N276A, H130N, N187S, Q170R, K171R, R169K, N160D, N160K, and T162A, which are encoded by nucleic acid molecules and potentially incorporated into nanoparticles, along with additional modifications like CD4-binding site germline targeting and Apex N160 glycan modifications, to induce a robust immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complex Env-antibody coevolution process is used to develop HIV antibodies, then broadly neutralizing antibodies can be elicited, but the development process becomes overly complex and difficult to control
Solution Approach 1:
The patent applies preliminary action by pre-introducing specific mutations into the Env antigen sequence before immunization. These mutations are designed to guide the immune system toward producing bNAbs, eliminating the need for complex in vivo coevolution processes. The mutations are selected based on their ability to elicit neutralizing antibodies against specific epitopes, thereby simplifying the overall development process while maintaining reliability.
Solution Approach 2:
The patent employs parameter changes by modifying specific amino acid residues in the Env antigen sequence. By changing parameters such as glycan composition, charge distribution, and conformational stability through targeted mutations, the antigen is optimized to elicit bNAbs more efficiently. This approach transforms the uncontrolled coevolution process into a directed engineering process with defined parameters.
2Reliability
If multiple mutations are introduced into the HIV envelope immunogen to induce bNAbs, then the immune response is enhanced, but the manufacturing precision and characterization become more difficult
Solution Approach 1:
The patent applies local quality by introducing mutations at specific, localized positions within the Env antigen sequence rather than throughout the entire protein. Each mutation is placed at a strategically important residue that influences antibody recognition or antigen conformation. This localized approach maintains manufacturing precision while achieving the desired immune response enhancement.
Solution Approach 2:
The patent uses copying by creating defined mutant versions of the Env antigen based on a well-characterized wild-type sequence. Each mutant is a precise copy with specific modifications, allowing for systematic production and characterization. The mutations are copied from known evolutionary variants or computationally designed sequences, enabling standardized manufacturing processes.
3Reliability
If HIV antigens are modified with multiple mutations and nanoparticle incorporation, then the immunogenicity is improved, but the ease of manufacture decreases
Solution Approach 1:
The patent applies segmentation by dividing the Env antigen into modular domains that can be independently engineered and assembled. The antigen is constructed from separate functional modules (e.g., gp120 variable regions, gp41 stem regions, nanoparticle binding domains) that can be produced and characterized separately before final assembly. This modular approach simplifies manufacturing while maintaining high immunogenicity.
Solution Approach 2:
The patent uses an intermediary approach by incorporating the modified Env antigen into nanoparticle carriers. The nanoparticle serves as an intermediary structure that simplifies formulation and delivery while enhancing immunogenicity through repeated antigen display and adjuvant effects. This intermediary system decouples the complexity of antigen engineering from the manufacturing process.
Data Source
AI summary
Disclosed herein are modified HIV envelope immunogens, engineered nanoparticle vaccines comprising modified HIV envelope immunogens and methods of use thereof for HIV vaccines.